A Prognostic Model to Predict Mortality among Non-Small-Cell Lung Cancer Patients in the U.S. Military Health System

Journal of Thoracic Oncology

Volumn 10, Issue 12, 2015, Pages 1694-1702

  Lin, Jie ^a   Carter, Corey A ^a   McGlynn, Katherine A ^b   Zahm, Shelia H ^b   Nations, Joel A ^a   Anderson, William F ^b   Shriver, Craig D ^a,c   Zhu, Kangmin ^a,d  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Departments of Surgery   (United States)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Military health system; Model; Mortality; Non small cell lung cancer; Risk prediction

Indexed keywords

ADULT; AGED; ARMY; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CEREBROVASCULAR DISEASE; CLINICAL DATA REPOSITORY; DIABETES MELLITUS; FEMALE; HEALTH CARE; HISTOPATHOLOGY; HUMAN; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PERIPHERAL VASCULAR DISEASE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA; SURVIVAL PREDICTION; TOBACCO USE; UNITED STATES; EPIDEMIOLOGY; LUNG TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RISK; SOLDIER; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MILITARY PERSONNEL; MODELS, STATISTICAL; PROGNOSIS; RISK; SURVIVAL ANALYSIS; UNITED STATES;

EID: 84948066493     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000691     Document Type: Article

References (43)

1. American Cancer Society. Available at: http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lungcancer-what-is-non-small-cell-lung-cancer. Accessed April 2014.
2. Howlader N NA, Krapcho M, Garshell J, et al. (Eds.). SEER Cancer Statistics Review, 1975-2011. Bethesda, MD: National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975-2011/, based on November 2013 SEER data submission, posted to the SEER web site. Accessed April 2014.
3. Osarogiagbon RU. Predicting survival of patients with resectable nonsmall cell lung cancer: Beyond TNM. J Thorac Dis 2012;4:214-216.
4. Kratz JR, He J, Van Den Eeden SK, et al. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet 2012;379:823-832.
5. Onn A, Dickey BF. A better crystal ball to predict lung-cancer survival Lancet Oncol 2006;7:789-790.
6. Park MJ, Jae Park M, Lee J, et al. Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment. Cancer 2009;115:1518-1530.
7. Dehing-Oberije C, Aerts H, Yu S, et al. Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325). Int J Radiat Oncol Biol Phys 2011;81:360-368.
8. Dehing-Oberije C, De Ruysscher D, van der Weide H, et al. Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-smallcell lung cancer patients treated with (chemo)radiotherapy. Int J Radiat Oncol Biol Phys 2008;70:1039-1044.
9. Dehing-Oberije C, Yu S, De Ruysscher D, et al. Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009;74:355-362.
10. Mandrekar SJ, Schild SE, Hillman SL, et al. A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials. Cancer 2006;107:781-792.
11. Hoang T, Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH. Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. J Thorac Oncol 2012;7:1361-1368.
12. Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH. Clinical model to predict survival in chemonaive patients with advanced non-smallcell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol 2005;23:175-183.
13. Blanchon F, Grivaux M, Asselain B, et al. 4-Year mortality in patients with non-small-cell lung cancer: development and validation of a prognostic index. Lancet Oncol 2006;7:829-836.
14. Putila J, Remick SC, Guo NL. Combining clinical, pathological, and demographic factors refines prognosis of lung cancer: a population-based study. PLoS One 2011;6:e17493.
15. Putila J, Guo NL. Combining COPD with clinical, pathological and demographic information refines prognosis and treatment response prediction of non-small cell lung cancer. PLoS One 2014;9:e100994.
16. Zhang M, Liu Y, Jiang Y, Sun Z, Yang P. Model based user interface design for predicting lung cancer treatment outcomes. Conf Proc IEEE Eng Med Biol Soc 2011;2011:75-78.
17. Gill AA, Enewold L, Zahm SH, et al. Colon cancer treatment: are there racial disparities in an equal-access healthcare system Dis Colon Rectum 2014;57:1059-1065.
18. Enewold L, McGlynn KA, Zahm SH, et al. Surveillance mammography among female Department of Defense beneficiaries: a study by race and ethnicity. Cancer 2013;119:3531-3538.
19. Zhou J, Enewold L, Zahm SH, et al. Breast conserving surgery versus mastectomy: the influence of comorbidities on choice of surgical operation in the Department of Defense health care system. Am J Surg 2013;206:393-399.
20. Andaya AA, Enewold L, Zahm SH, et al. Race and colon cancer survival in an equal-access health care system. Cancer Epidemiol Biomarkers Prev 2013;22:1030-1036.
21. Enewold L, Zhou J, McGlynn KA, et al. Racial variation in breast cancer treatment among Department of Defense beneficiaries. Cancer 2012;118:812-820.
22. Fritz A, Percy C, Jack A. International Classification of Diseases for Oncology, 3rd Ed. Geneva: World Health Organization; 2000.
23. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000;56:337-344.
24. D'Agostino RD, Nam BH. Evaluation of performance of survival analysis models: discrimination and calibration measures. In: Balakrishnan N, Rao CR (Eds.). Handbook of Statistics, Vol. 23. Amsterdam: Elsevier; 2004. Pp. 1-25.
25. Sullivan LM, Massaro JM, D'Agostino Sr. R.B. Presentation of multivariate data for clinical use: The Framingham study risk score functions. Stat Med 2004;23:1631-1660.
26. Hosmer DW, Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data. New York: John Wiley & Sons, Inc.; 1999.
27. Williams BA, Sugimura H, Endo C, et al. Predicting postrecurrence survival among completely resected nonsmall-cell lung cancer patients. Ann Thorac Surg 2006;81:1021-1027.
28. Sawyer TE, Bonner JA, Gould PM, Deschamps C, Lange CM, Li H. Patients with stage I non-small cell lung carcinoma at postoperative risk for local recurrence, distant metastasis, and death: implications related to the design of clinical trials. Int J Radiat Oncol Biol Phys 1999;45:315-321.
29. Zheng L, Enewold L, Zahm SH, et al. Lung cancer survival among black and white patients in an equal access health system. Cancer Epidemiol Biomarkers Prev 2012;21:1841-1847.
30. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002;122:1037-1057.
31. Yang P. Epidemiology of lung cancer prognosis: quantity and quality of life. Methods Mol Biol 2009;471:469-486.
32. Chiou WK, Hwang JS, Hsu KH, Lin JD. Diabetes mellitus increased mortality rates more in gender-specific than in nongender-specific cancer patients: a retrospective study of 149,491 patients. Exp Diabetes Res 2012;2012:701643.
33. Shieh SH, Probst JC, Sung FC, Tsai WC, Li YS, Chen CY. Decreased survival among lung cancer patients with co-morbid tuberculosis and diabetes. BMC Cancer 2012;12:174.
34. Tseng CH. Higher risk of mortality from lung cancer in Taiwanese people with diabetes. Diabetes Res Clin Pract 2013;102:193-201.
35. Inal A, Kaplan MA, Kucukoner M, Urakc Z, Klnc F, Iskdogan A. Is diabetes mellitus a negative prognostic factor for the treatment of advanced non-small-cell lung cancer Rev Port Pneumol 2014;20:62-68.
36. Ioacara S, Guja C, Ionescu-Tirgoviste C, Fica S, Roden M. Cancer specific mortality in insulin-treated type 2 diabetes patients. PLoS One 2014;9:e93132.
37. Battafarano RJ, Piccirillo JF, Meyers BF, et al. Impact of comorbidity on survival after surgical resection in patients with stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 2002;123:280-287.
38. Ahn DH, Mehta N, Yorio JT, Xie Y, Yan J, Gerber DE. Influence of medical comorbidities on the presentation and outcomes of stage I-III nonsmall-cell lung cancer. Clin Lung Cancer 2013;14:644-650.
39. Xie Y, Minna JD. Predicting the future for people with lung cancer. Nat Med 2008;14:812-813.
40. Xie Y, Minna JD. A lung cancer molecular prognostic test ready for prime time. Lancet 2012;379:785-787.
41. Shedden K, Taylor JM, Enkemann SA, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008;14:822-827.
42. Lee CK, Brown C, Gralla RJ, et al. Impact of EGFR inhibitor in nonsmall cell lung cancer on progression-free and overall survival: a metaanalysis. J Natl Cancer Inst 2013;105:595-605.
43. Gegg-Harrison T, Zhang M, Meng N, Sun Z, Yang P. Porting a cancer treatment prediction to a mobile device. Conf Proc IEEE Eng Med Biol Soc 2009;2009:6218-6221.